Invesco Biotechnology & Genome ETF
$96.31−1.36 (−1.39%)
- Expense ratio
- 0.59%
- Fund size
- $418M
- 1Y return
- +41.0%
- Yield · Last 12 months
- 1.36%
- Holdings
- 31
- Volume · 30D
- 0M sh
- NAV per share
- $95.91
- 52W range
The ETF.net PBE Grade
Score 55 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.FScore 19Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 91Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 60Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.BScore 60Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.CScore 48Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 78Category rank
Our read on PBE
CMost biotech ETFs buy the whole sector. PBE screens it, ranking names on momentum, quality and value, then holding about 30 US biotech and genome stocks. A quant stock-picker wearing index clothing.
The Fund seeks to track, before fees and expenses, the results of its designated biotechnology and genome benchmark index.
Why people hold it
- The Intellidex index rates companies on price momentum, earnings momentum, quality, management action and value, then lands on about 30 names. Selection, not sector beta.invesco.com
- Trading since 2005, it has been through several full biotech boom-and-bust cycles. Long tenure for a thematic fund.invesco.com
- No mandate drift: the stated job is tracking a US biotechnology and genome index, and the portfolio stays inside that lane.
- Normally keeps at least 90% of total assets in index securities, so what you see in the methodology is what you own.invesco.com
Worth knowing
- At 0.58% a year it charges more than the typical biotech ETF, and the big cap-weighted rivals (IBB, XBI, IBBQ) list lower fees. The screen isn't free.
- Roughly 30 holdings and a non-diversified structure: one bad trial readout lands harder here than in an index spread across hundreds of names.money.usnews.com
- Thinly traded next to the category's giants, so bid-ask spreads can run wider. Limit orders matter more with a fund like this.
PBE Holdings
- Stocks
- 31
- 47%
- NTRA
Sectors
- Health Care99.9%
- Financials0.1%
Geography
- United States97.25%
- Netherlands2.75%
PBE Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PBE |
|---|---|
| Year to date | +20.2% |
| 1 month | +0.1% |
| 3 months | +15.3% |
| 1 year | +41.0% |
| 3 years | +20.2% |
| 5 years | +5.4% |
| 10 years | +8.7% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PBE |
|---|---|---|
| 2026 YTD | +20.2% | |
| 2025 | +24.8% | |
| 2024 | +1.1% | |
| 2023 | +3.7% | |
| 2022 | −10.8% | |
| 2021 | +1.5% | |
| 2020 | +25.7% |
PBE in the news
ETF.net Research hasn’t filed on PBE yet — coverage lands here as it’s written.
PBE Dividends
- 1.36%
- $1.33
- $0.02 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 21, 2026 | Pays Sep 25, 2026 | $0.02 |
| Jun 22, 2026 | Jun 26, 2026 | $0.81 |
| Mar 23, 2026 | Mar 27, 2026 | $0.08 |
| Dec 22, 2025 | Dec 26, 2025 | $0.42 |
| Sep 22, 2025 | Sep 26, 2025 | $0.23 |
| Jun 23, 2025 | Jun 27, 2025 | $0.13 |
| Mar 24, 2025 | Mar 28, 2025 | $0.03 |
| Jun 24, 2024 | Jun 28, 2024 | $0.0082 |
| Mar 18, 2024 | Mar 22, 2024 | $0.02 |
| Jun 20, 2023 | Jun 23, 2023 | $0.01 |
| Mar 23, 2020 | Mar 31, 2020 | $0.03 |
| Sep 24, 2018 | Sep 28, 2018 | $0.0021 |
PBE Risk
- 17.6%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.73
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −33.3%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.79
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PBE Cost
- The middle half of Biotech & Genomics funds
- Median 0.47%
12 of the 15 Biotech & Genomics funds charge less.